Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00000069.xml
Download PDF
CC BY-NC-ND 4.0 · Semin Liver Dis 2024; 44(03): 356-368
DOI: 10.1055/a-2378-8942
DOI: 10.1055/a-2378-8942
Review Article
The Value of Ammonia as a Biomarker in Patients with Cirrhosis
Financial Declarations M.P.B. has a Juan Rodes contract from Instituto de Salud Carlos III (JR23/00029).
Abstract
Ammonia is a product of amino acid metabolism that accumulates in the blood of patients with cirrhosis and plays a pivotal role in the pathogenesis of hepatic encephalopathy (HE). Despite being one of the main drivers of brain dysfunction, for many years international societies stated that increased blood ammonia does not add any diagnostic, staging, or prognostic value for HE in patients with cirrhosis. Nonetheless, in the last decades, evidence is emerging that supports the utility of ammonia for risk stratification, but its role in guiding HE diagnosis, staging, and treatment is unclear and there is equipoise in its use in clinical practice. This review provides the latest evidence on the value of ammonia as a biomarker in patients with cirrhosis. Although correct measurement of ammonia requires disciplined sample collection, it provides extremely useful clinical guidance for the diagnosis of HE, offers prognostic information, and it defines a therapeutic target.
* Shared first author
Publication History
Accepted Manuscript online:
02 August 2024
Article published online:
03 September 2024
© 2024. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/)
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Vilstrup H, Amodio P, Bajaj J. et al. Hepatic encephalopathy in chronic liver disease: 2014 Practice Guideline by the American Association for the Study of Liver Diseases and the European Association for the Study of the Liver. Hepatology 2014; 60 (02) 715-735
- 2 European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu, European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatic encephalopathy. J Hepatol 2022; 77 (03) 807-824
- 3 Tapper EB, Henderson JB, Parikh ND, Ioannou GN, Lok AS. Incidence of and risk factors for hepatic encephalopathy in a population-based cohort of Americans with cirrhosis. Hepatol Commun 2019; 3 (11) 1510-1519
- 4 Casadaban LC, Parvinian A, Minocha J. et al. Clearing the confusion over hepatic encephalopathy after TIPS creation: incidence, prognostic factors, and clinical outcomes. Dig Dis Sci 2015; 60 (04) 1059-1066
- 5 Arguedas MR, DeLawrence TG, McGuire BM. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003; 48 (08) 1622-1626
- 6 Tapper EB, Halbert B, Mellinger J. Rates of and reasons for hospital readmissions in patients with cirrhosis: a multistate population-based cohort study. Clin Gastroenterol Hepatol 2016; 14 (08) 1181-1188.e2
- 7 Bosoi CR, Rose CF. Identifying the direct effects of ammonia on the brain. Metab Brain Dis 2009; 24 (01) 95-102
- 8 Angelova PR, Kerbert AJC, Habtesion A, Hall A, Abramov AY, Jalan R. Hyperammonaemia induces mitochondrial dysfunction and neuronal cell death. JHEP Rep Innov Hepatol 2022; 4 (08) 100510
- 9 Häussinger D, Dhiman RK, Felipo V. et al. Hepatic encephalopathy. Nat Rev Dis Primers 2022; 8 (01) 43
- 10 Patwardhan VR, Jiang ZG, Risech-Neiman Y. et al. Serum ammonia is associated with transplant-free survival in hospitalized patients with acutely decompensated cirrhosis [corrected]. J Clin Gastroenterol 2016; 50 (04) 345-350
- 11 Shalimar, Sheikh MF, Mookerjee RP, Agarwal B, Acharya SK, Jalan R. Prognostic role of ammonia in patients with cirrhosis. Hepatology 2019; 70 (03) 982-994
- 12 Nicolao F, Efrati C, Masini A, Merli M, Attili AF, Riggio O. Role of determination of partial pressure of ammonia in cirrhotic patients with and without hepatic encephalopathy. J Hepatol 2003; 38 (04) 441-446
- 13 Gundling F, Zelihic E, Seidl H. et al. How to diagnose hepatic encephalopathy in the emergency department. Ann Hepatol 2013; 12 (01) 108-114
- 14 Ong JP, Aggarwal A, Krieger D. et al. Correlation between ammonia levels and the severity of hepatic encephalopathy. Am J Med 2003; 114 (03) 188-193
- 15 Sawhney R, Holland-Fischer P, Rosselli M, Mookerjee RP, Agarwal B, Jalan R. Role of ammonia, inflammation, and cerebral oxygenation in brain dysfunction of acute-on-chronic liver failure patients. Liver Transpl 2016; 22 (06) 732-742
- 16 Rose CF, Amodio P, Bajaj JS. et al. Hepatic encephalopathy: novel insights into classification, pathophysiology and therapy. J Hepatol 2020; 73 (06) 1526-1547
- 17 Tranah TH, Ballester MP, Carbonell-Asins JA. et al. Plasma ammonia levels predict hospitalisation with liver-related complications and mortality in clinically stable outpatients with cirrhosis. J Hepatol 2022; 77 (06) 1554-1563
- 18 Balcar L, Krawanja J, Scheiner B. et al. Impact of ammonia levels on outcome in clinically stable outpatients with advanced chronic liver disease. JHEP Rep Innov Hepatol 2023; 5 (04) 100682
- 19 Ballester MP, Tranah TH, Balcar L. et al. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis. J Hepatol 2023; 79 (04) 967-976
- 20 Shalimar, Rout G, Kumar R. et al. Persistent or incident hyperammonemia is associated with poor outcomes in acute decompensation and acute-on-chronic liver failure. JGH Open 2020; 4 (05) 843-850
- 21 Hu C, Huang K, Zhao L, Zhang F, Wu Z, Li L. Serum ammonia is a strong prognostic factor for patients with acute-on-chronic liver failure. Sci Rep 2020; 10 (01) 16970
- 22 Elzeftawy A, Mansour L, Kobtan A, Mourad H, El-Kalla F. Evaluation of the blood ammonia level as a non-invasive predictor for the presence of esophageal varices and the risk of bleeding. Turk J Gastroenterol 2019; 30 (01) 59-65
- 23 Darweesh SK, Elsabaawy MA, Eltahawy MA, Ghanem HS, Abdel-Razek W. Serum ammonia as a non-invasive marker for early prediction of esophageal varices. Eur J Gastroenterol Hepatol 2021; 32 (02) 230-236
- 24 El-Kalla F, Mansour L, Kobtan A. et al. Blood ammonia level correlates with severity of cirrhotic portal hypertensive gastropathy. Gastroenterol Res Pract 2018; 2018: 9067583
- 25 Bellafante D, Gioia S, Faccioli J, Riggio O, Ridola L, Nardelli S. Old and new precipitants in hepatic encephalopathy: a new look at a field in continuous evolution. J Clin Med 2023; 12 (03) 1187
- 26 Rahimi RS, Brown KA, Flamm SL, Brown Jr RS. Overt hepatic encephalopathy: current pharmacologic treatments and improving clinical outcomes. Am J Med 2021; 134 (11) 1330-1338
- 27 Eriksen PL, Djernes L, Vilstrup H, Ott P. Clearance and production of ammonia quantified in humans by constant ammonia infusion - the effects of cirrhosis and ammonia-targeting treatments. J Hepatol 2023; 79 (02) 340-348
- 28 Pockros P, Hassanein T, Vierling J. et al. Phase 2, multicenter, randomized study of AST-120 (spherical carbon adsorbent) vs. Lactulose in the treatment of low-grade hepatic encephalopathy (HE). J Hepatol 2009; 50 (supple):S43
- 29 Rahimi RS, Safadi R, Thabut D. et al. Efficacy and safety of ornithine phenylacetate for treating overt hepatic encephalopathy in a randomized trial. Clin Gastroenterol Hepatol 2021; 19 (12) 2626-2635.e7
- 30 Deutsch-Link S, Moon AM, Jiang Y, Barritt IV AS, Tapper EB. Serum ammonia in cirrhosis: clinical impact of hyperammonemia, utility of testing, and national testing trends. Clin Ther 2022; 44 (03) e45-e57
- 31 Hannah N, Vasic D, Kansal A, Al-Ani A, Hebbard G, Sood S. Serum ammonia does not guide management and is overutilised in patients with cirrhosis in hospital settings. Intern Med J 2023; 53 (11) 2057-2064
- 32 Haj M, Rockey DC. Ammonia levels do not guide clinical management of patients with hepatic encephalopathy caused by cirrhosis. Am J Gastroenterol 2020; 115 (05) 723-728
- 33 Gairing SJ, Kaps L, Schleicher EM, Galle PR, Labenz C. Ammonia - an old friend with a new area of application. J Hepatol 2023; 78 (01) e22-e23
- 34 Wang X, Zhang M, Xiao J. et al. A modified Child-Turcotte-Pugh score based on plasma ammonia predicts survival for patients with decompensated cirrhosis. QJM 2023; 116 (06) 436-442
- 35 Ehrenbauer AF, Egge JFM, Gabriel MM. et al. Comparison of 6 tests for diagnosing minimal hepatic encephalopathy and predicting clinical outcome: a prospective, observational study. Hepatology 2024; 80 (02) 389-402
- 36 Hansen MKG, Kjærgaard K, Eriksen LL. et al. Psychometric methods for diagnosing and monitoring minimal hepatic encephalopathy -current validation level and practical use. Metab Brain Dis 2022; 37 (03) 589-605
- 37 Cardoso FS, Kim M, Pereira R. et al. Early serum ammonia variation in critically ill patients with cirrhosis: a multicentre cohort study. Aliment Pharmacol Ther 2023; 58 (07) 715-724
- 38 Verma N, Dhiman RK, Choudhury A. et al; APASL ACLF Research Consortium (AARC) for APASL ACLF working Party. Dynamic assessments of hepatic encephalopathy and ammonia levels predict mortality in acute-on-chronic liver failure. Hepatol Int 2021; 15 (04) 970-982
- 39 Chiriac S, Stanciu C, Cojocariu C. et al. Role of ammonia in predicting the outcome of patients with acute-on-chronic liver failure. World J Clin Cases 2021; 9 (03) 552-564
- 40 Thanapirom K, Treeprasertsuk S, Choudhury A. et al. Ammonia is associated with liver-related complications and predicts mortality in acute-on-chronic liver failure patients. Sci Rep 2024; 14 (01) 5796
- 41 Tandon P, Montano-Loza AJ, Lai JC, Dasarathy S, Merli M. Sarcopenia and frailty in decompensated cirrhosis. J Hepatol 2021; 75 (Suppl 1, Suppl 1): S147-S162
- 42 Ebadi M, Bhanji RA, Mazurak VC, Montano-Loza AJ. Sarcopenia in cirrhosis: from pathogenesis to interventions. J Gastroenterol 2019; 54 (10) 845-859
- 43 Chang KV, Chen JD, Wu WT, Huang KC, Lin HY, Han DS. Is sarcopenia associated with hepatic encephalopathy in liver cirrhosis? A systematic review and meta-analysis. J Formos Med Assoc 2019; 118 (04) 833-842
- 44 Lattanzi B, D'Ambrosio D, Merli M. Hepatic encephalopathy and sarcopenia: two faces of the same metabolic alteration. J Clin Exp Hepatol 2019; 9 (01) 125-130
- 45 Jindal A, Jagdish RK. Sarcopenia: ammonia metabolism and hepatic encephalopathy. Clin Mol Hepatol 2019; 25 (03) 270-279
- 46 Di Cola S, Nardelli S, Ridola L, Gioia S, Riggio O, Merli M. Ammonia and the muscle: an emerging point of view on hepatic encephalopathy. J Clin Med 2022; 11 (03) 611
- 47 Qiu J, Thapaliya S, Runkana A. et al. Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci U S A 2013; 110 (45) 18162-18167
- 48 Davuluri G, Krokowski D, Guan BJ. et al. Metabolic adaptation of skeletal muscle to hyperammonemia drives the beneficial effects of l-leucine in cirrhosis. J Hepatol 2016; 65 (05) 929-937
- 49 Davuluri G, Allawy A, Thapaliya S. et al. Hyperammonaemia-induced skeletal muscle mitochondrial dysfunction results in cataplerosis and oxidative stress. J Physiol 2016; 594 (24) 7341-7360
- 50 Kumar A, Davuluri G, Silva RNE. et al. Ammonia lowering reverses sarcopenia of cirrhosis by restoring skeletal muscle proteostasis. Hepatology 2017; 65 (06) 2045-2058
- 51 Butterworth RF. L-Ornithine L-aspartate for the treatment of sarcopenia in chronic liver disease: the taming of a vicious cycle. Can J Gastroenterol Hepatol 2019; 2019: 8182195
- 52 Hirooka M, Koizumi Y, Tanaka T. et al. Treatment on the spleen prevents the progression of secondary sarcopenia in patients with liver cirrhosis. Hepatol Commun 2020; 4 (12) 1812-1823
- 53 Chen HW, Dunn MA. Muscle at risk: the multiple impacts of ammonia on sarcopenia and frailty in cirrhosis. Clin Transl Gastroenterol 2016; 7 (05) e170
- 54 Albillos A, Martin-Mateos R, Van der Merwe S, Wiest R, Jalan R, Álvarez-Mon M. Cirrhosis-associated immune dysfunction. Nat Rev Gastroenterol Hepatol 2022; 19 (02) 112-134
- 55 Mookerjee RP, Stadlbauer V, Lidder S. et al. Neutrophil dysfunction in alcoholic hepatitis superimposed on cirrhosis is reversible and predicts the outcome. Hepatology 2007; 46 (03) 831-840
- 56 Shawcross DL, Wright GA, Stadlbauer V. et al. Ammonia impairs neutrophil phagocytic function in liver disease. Hepatology 2008; 48 (04) 1202-1212
- 57 Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010; 51 (03) 1062-1069
- 58 Breheny CR, Mellanby RJ, Hamilton JA, Gow AG. The effect of ammonia on canine polymorphonuclear cells. Vet Res Commun 2018; 42 (03) 221-225
- 59 Coppi M, Niederman R. Effects of ammonia on human neutrophil N-formyl chemotactic peptide receptor-ligand interaction and cytoskeletal association. Biochem Biophys Res Commun 1989; 165 (01) 377-383
- 60 Luo C, Shen G, Liu N. et al. Ammonia drives dendritic cells into dysfunction. J Immunol 2014; 193 (03) 1080-1089
- 61 Alabsawy E, Shalimar, Sheikh MF. et al. Overt hepatic encephalopathy is an independent risk factor for de novo infection in cirrhotic patients with acute decompensation. Aliment Pharmacol Ther 2022; 55 (06) 722-732
- 62 Ballester MP, Rose CF, Carbonell-Asins JA, Jalan R. Measuring and Interpreting Ammonia Levels in Cirrhosis. Am J Gastroenterol 2023; 118 (07) 1297